Paradigm Biopharmaceuticals (PAR.ASX) Livewire Interview

Michael Goldberg (Managing Director and Portfolio Manager of the Collins St Value Fund) provides an overview of the investment thesis supporting the Funds’ investment into the ASX listed Paradigm Biopharmaceuticals.

Share on facebook
Share on email
Share on twitter